OncoMatch/Clinical Trials/NCT06651229
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Is NCT06651229 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JNJ-90189892 for leukemia, myeloid, acute.
Treatment: JNJ-90189892 — The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose\[s\] \[RP2Ds\]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
laboratory parameters in the required range
Kidney function
CKD-EPI eGFR >=40 mL/min computed with the calculator on the CKD-EPI website
adequate renal function defined as CKD-EPI eGFR >=40 mL/min ... laboratory parameters in the required range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify